Jennifer Carney
Hematology & Oncology · Honolulu, HINPI 1548370604
Payments from drug & device makers
What this record shows
That places this record below the midpoint for hematology & oncology clinicians in HI, where the typical reported total is $1,482.
No general payments reported
No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.
$1,861,384in research payments, 2019–2025
Across 223 payments — averaging $8347.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$579K
- Seagen Inc.$309K
- Merck$233K
- Eli Lilly$167K
- Genentech, Inc.$121K
- AstraZeneca$101K
- plus $352K from 15 others
How this compares
$0 in reported general payments places this provider in the 0th percentile of 42 hematology & oncology providers in Hawaii.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 27 | $419,970 |
| PomalystPomalidomide | 13 | $314,548 |
| AlecensaAlectinib Hcl | 15 | $301,078 |
| BrukinsaZanubrutinib | 16 | $209,466 |
| TagrissoOsimertinib Mesylate | 11 | $188,833 |
| Lenalidomide | 13 | $169,874 |
| AlvaizEltrombopag Choline | 11 | $39,330 |
| Anastrozole | 73 | $1,996 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 11 | $1,617 |
| Tamoxifen Citrate | 48 | $1,510 |
| Exemestane | 14 | $1,138 |
| Letrozole | 36 | $410 |
| Dexamethasone | 18 | $222 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Honolulu
- Tamie KernsHonolulu$48K
- David TamuraHonolulu$31K
- Melvin PalalayHonolulu$20K
- Ryon NakasoneHonolulu$20K
- Arnold YeeHonolulu$17K
- Jared AcobaHonolulu$15K
- Swaty AroraHonolulu$15K
- William LouiHonolulu$12K
- Jodi KagiharaHonolulu$7K
- Nicolas VillanuevaHonolulu$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.